Inhibrx Biosciences, Inc. (INBX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 600K 1.2M 1.8M Q1 '23: 17K Q2 '23: 30K Q3 '23: 119K Q4 '23: 1.6M Q1 '24: 0 Q2 '24: 100K Q3 '24: 0 Q4 '24: 100K Q1 '25: 0 Q2 '25: 1.3M Q3 '25: 0 Q4 '25: 0 Q2 '26: 0 Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q1 '23: -43.8M Q2 '23: -41.3M Q3 '23: -45.8M Q4 '23: -88.3M Q1 '24: -73.8M Q2 '24: -160.9M Q3 '24: -46.8M Q4 '24: -49.9M Q1 '25: -42.9M Q2 '25: -27.4M Q3 '25: -33.8M Q4 '25: -30.9M Q1 '26: -30.9M Q2 '26: -32.1M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Net Income Quarterly

-700M 0 700M 1.4B 2.1B Q1 '23: -48.9M Q2 '23: -47.1M Q3 '23: -51.8M Q4 '23: -93.6M Q1 '24: -78.7M Q2 '24: 1.9B Q3 '24: -43.9M Q4 '24: -47.9M Q1 '25: -43.3M Q2 '25: -28.7M Q3 '25: -35.3M Q4 '25: -32.8M Q1 '26: -33.4M Q2 '26: -36.6M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '23: -54.2M Q4 '23: -56.8M Q1 '24: -63M Q2 '24: -57.4M Q3 '24: -30.3M Q4 '24: -43.7M Q1 '25: -35.9M Q2 '25: -30M Q3 '25: -33.8M Q4 '25: -30.1M Q1 '26: -38M Q2 '26: -29.9M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '23: -55.1M Q4 '23: -60.3M Q1 '24: -64.2M Q2 '24: -58.6M Q3 '24: -30.5M Q4 '24: -43.7M Q1 '25: -35.9M Q2 '25: -30M Q3 '25: -33.8M Q4 '25: -30.1M Q1 '26: -38M Q2 '26: -29.9M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q2 '23: 10.9M Q3 '23: 11.8M Q1 '24: 13.6M Q2 '24: 14.8M Q3 '24: 15.5M Q1 '25: 15.5M Q2 '25: 15.5M Q3 '25: 15.5M Q1 '26: 15.6M Q2 '26: 15.7M Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-40.00 0.00 40.00 80.00 120.00 Q4 '23: -20.48 Q1 '24: -21.76 Q2 '24: 108.03 Q3 '24: 109.58 Q4 '24: 112.62 Q1 '25: 115.59 Q2 '25: -11.74 Q3 '25: -11.18 Q4 '25: -9.04 Q1 '26: -8.39 Q2 '26: -8.88 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.